Verzenio vs Lynparza
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
| US Verzenio | US Lynparza | |
|---|---|---|
| Generic name | abemaciclib | olaparib |
| Drug class | CDK4/6 Inhibitor | PARP Inhibitor |
| Treats | HR+/HER2- breast cancer | Ovarian, breast, prostate, and pancreatic cancers |
| Category | Oncology | Oncology |
| Manufacturer | Eli Lilly | AstraZeneca |
| Year approved | 2017 | 2014 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $85M | — |
| Common side effects | Diarrhea, Low blood counts, Fatigue, Blood clots | Nausea, Fatigue, Low blood counts, Risk of blood cancers (MDS/AML) |
Frequently asked questions
Is Verzenio or Lynparza better?
Neither is universally "better." Verzenio (abemaciclib) and Lynparza (olaparib) are both used for oncology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Verzenio and Lynparza?
Verzenio is a CDK4/6 Inhibitor made by Eli Lilly, while Lynparza is a PARP Inhibitor made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Verzenio has the larger estimated TV advertising budget of the two.